Salarius Pharmaceuticals Company Research Report

Company Overview

Name: Salarius Pharmaceuticals

Mission: Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options. Their technologies correct the dysregulated gene expression of cancer cells.

Founded: No information is available

Founders: No information is available

Key People in the Company:

David J. Arthur: Chief Executive Officer

Mark J. Rosenblum: Chief Financial Officer

Nadeem Q. Mirza, MD, MPH: Senior Vice President, Clinical Development

Rebecca Griffith-Eskew: Vice President, Clinical Operations

William McVicar, PhD: Chairman, Board of Directors

Jonathan Lieber: Board of Directors

Tess Burleson, MBA, CPA: Board of Directors

Paul Lammers, MD, MSc: Board of Directors

Bruce McCreedy, PhD: Board of Directors

Arnold C. Hanish, CPA: Board of Directors

Headquartered: Texas Medical Center Innovation facility in Houston, Texas

Number of Employees: No information is available

Revenue: No information is available

What the Company is Known For: Salarius Pharmaceuticals is known for developing therapies targeting dysregulated gene expression in cancer cells, particularly through targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs).

Products

SP-2577 (Seclidemstat)

Description:

SP-2577 (Seclidemstat) is a targeted LSD1 inhibitor that interferes with the epigenetic processes involved in cancer growth.

Clinical trials are underway for Ewing sarcoma, myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML).

Key Features:

Inhibits enzymatic activity and scaffolding function of LSD1.

Being studied in combination with other therapies to improve treatment outcomes.

Demonstrated tolerability and preliminary activity in phase 1/2 trials.

SP-3164

Description:

SP-3164 is a targeted protein degrader acting as a molecular glue to facilitate selective degradation of cancer-promoting proteins.

It is designed to treat hematological and solid tumors.

Key Features:

Degrades transcription factors Ikaros (IKZF1) and Aiolos (IKZF3).

Uses deuterium-enabled chiral switching (DECS) to improve stability and efficacy.

Expected to enter clinical trials in the second half of 2023.

Recent Developments

Acquisitions and Partnerships

January 13, 2022: Salarius expanded its oncology pipeline through the acquisition of the Targeted Protein Degradation Portfolio from DeuteRx, LLC.

Clinical Trials and Presentations

June 17, 2024: Clinical data on Seclidemstat in patients with MDS and CMML was presented at the 2024 European Hematology Association Annual Meeting.

July 12, 2023: Salarius Pharmaceuticals cleared to begin Phase I trial of SP-3164 in non-Hodgkin Lymphoma.

November 2024 (Expected): Further clinical trials of SP-2577 in combination with azacitidine for MDS and CMML, as well as trials for other hematologic cancers and specific gynecologic cancers.

Financial and Corporate Updates

June 12, 2024: Announced a 1-for-8 reverse stock split.

March 22, 2024: Reported financial results for the fourth quarter and full year of 2023, along with business updates.

February 22, 2024: Updated on the strategic review process and plans to support ongoing clinical trials by further reducing expenses.

Events and Conferences

July 11, 2023: Participated in the 11th Annual Tumor Models Conference.

June 8-11, 2023: Attended EHA 2023 Hybrid Congress in Frankfurt, Germany.

April 14-19, 2023: Participated in the AACR Annual Meeting 2023.

Publications

Salarius' targeted protein inhibitors and degraders were the subjects of multiple studies and reviews published in high-profile journals, highlighting the potential and progress of their technologies in cancer treatment.

Summary

Salarius Pharmaceuticals focuses on developing innovative therapies targeting gene dysregulation in cancer cells through their programs in targeted protein inhibition and degradation. With key product candidates in clinical trials and significant partnerships and acquisitions, the company is advancing its mission to bring new treatment options to cancer patients. Despite some financial restructuring, Salarius continues to push forward with its promising pipeline of oncology products.